Evidence map›Paper›PMID 27788571›Full record

ArticleInternational journal of stem cells2016

Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.

Nassim Abi Chahine, Tarek Wehbe, Johny Rashed, Ramzi Hilal, Nada Elias

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of stem cells, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nassim Abi ChahineDepartment of Neurosurgery, The Lebanese-Canadian Hospital, Beirut, Lebanon.
Tarek WehbeDepartment of Hematology, The Lebanese-Canadian and Notre Dame University Hospital, Beirut, Lebanon.
Johny RashedDepartment of Biology, University of Balamand, Balamand, Lebanon.
Ramzi HilalDepartment of Neurology, The Lebanese-Canadian Hospital, Beirut, Lebanon.
Nada EliasNeuro- rehabilitation, Physical Therapy, Beirut, Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cell therapy, an evolving, progressive field of therapeutics has shown several successes in areas where classic treatments failed to prevent or stop disability. Starting in 2009, twenty two sequential patients with progressive Multiple Sclerosis (MS) courses were treated with Autologous Bone Marrow Mononuclear stem cells (BM-MNSCs). The cells were given both intravenously and intrathecally. Using the Expanded Disability Status Scale (EDSS) score for evaluation, our data indicates that the majority of the patients benefited on the average one point on the scale. This paper adds to the body of evidence suggesting the safety and efficacy of autologous BM-MNSCs in the treatment of MS and awaits validation through larger, randomized studies.

Indexed as

Autologous bone marrowMononuclear cellsMultiple SclerosisStem cellsThe expanded disability status scale

Identifiers

PMID27788571
PMCPMC5155716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.